false
0001533743
0001533743
2024-08-28
2024-08-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): August 28, 2024
Commission
file number 001-39531
PROCESSA
PHARMACEUTICALS, INC.
(Exact
name of Registrant as Specified in its Charter)
Delaware |
|
45-1539785 |
(State
or Other Jurisdiction of
Incorporation or Organization) |
|
(I.R.S.
Employer
Identification Number) |
7380
Coca Cola Drive, Suite 106, Hanover, Maryland 21076 |
(Address
of Principal Executive Offices, Including Zip Code) |
(443)
776-3133 |
(Registrant’s
Telephone Number, Including Area Code) |
|
(Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
Common
stock: Par value $.0001 |
|
PCSA |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Event.
On
August 28, 2024, Processa Pharmaceuticals, Inc., (The “Company”) issued a press release providing updates on its product
pipeline, upcoming milestones and business activities, and reports financial results for the three and six months ended June 30, 2024.
Safe
Harbor Statement
Information
provided in this Current Report on Form 8-K may contain statements relating to current expectations, estimates, forecasts and projections
about future events that are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995.
These forward-looking statements generally relate to the Company’s plans, objectives and expectations for compensation matters
related to Mr. Skibsted’s service as the Company’s Chief Financial Officer and Mr. Skibsted’s start date. Actual future
results may differ materially from those projected as a result of certain risks and uncertainties. For a discussion of such risks and
uncertainties, see “Risk Factors” as described in the Company’s Annual Report for the year ended December 31, 2023
on Form 10-K filed with the Commission on March 30, 2023, the Company’s Quarterly Report on Form 10-Q for the quarter ended March
31, 2024 filed with the Commission on May 10, 2024, and other reports on file with the Commission.
These
forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking
statements, whether as a result of new information, future events or otherwise.
Item
9.01. Financial Statements and Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized, on August 28, 2024.
|
PROCESSA
PHARMACEUTICALS, INC. |
|
Registrant |
|
|
|
|
By: |
/s/
George Ng |
|
|
George
Ng |
|
|
Chief
Executive Officer |
Exhibit
99.1
![Z:2024 OPERATIONSEDGAR08 AUGUSTPROCESSA PHARMACEUTICALS, INC08-27-2024Form8-K(August 28, 2024)DraftProduction](https://www.sec.gov/Archives/edgar/data/1533743/000149315224034115/ex99-1_001.jpg)
Processa
Pharmaceuticals Provides Product Pipeline and Financial Update
Phase
2 trial with NGC-Cap in breast cancer underway
NGC-Cap
Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity
Preclinical
studies demonstrated NGC-Iri delivers more cancer-killing SN-38 molecules to tumor than either irinotecan or Onivyde®
HANOVER,
Md., August 28, 2024 – Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical
company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, provides updates on its
product pipeline, upcoming milestones and business activities, and reports financial results for the three and six months ended June
30, 2024.
“We
made significant progress in advancing our three development programs year-to-date, with a particular focus on our lead candidate NGC-Cap,”
said George Ng, Chief Executive Officer of Processa Pharmaceuticals. “Upon receiving FDA clearance of our NGC-Cap IND application,
we initiated a Phase 2 clinical trial in metastatic breast cancer. We look forward to enrolling patients in this multicenter, open-label
study and expect to have an initial data readout in mid-2025.”
Key
Program Updates
Processa
is focused on developing next-generation chemotherapies (NGC) by improving widely used U.S. Food and Drug Administration (FDA)-approved
oncology drugs to extend a patient’s survival and/or improve their quality of life. This is achieved by altering how drugs are
metabolized and/or distributed in the body, including how they reach cancer cells. In addition, Processa utilizes its Regulatory Science
Approach, including the principles associated with FDA’s Project Optimus Oncology initiative, in the development of its NGC drug
products to achieve a more favorable benefit-risk profile.
Processa’s
updated corporate presentation, including its product pipeline, is available on the company’s website.
| ● | PCS6422:
Next-Generation Capecitabine (NGC-Cap) |
| ○ | NGC-Cap
is a combination of PCS6422 and capecitabine, which is the oral prodrug of the cancer drug
5-fluorouracil (5-FU). PCS6422 alters the metabolism of 5-FU, resulting in more 5-FU distributed
to cancer cells. |
| ○ | In
July 2024, the FDA cleared the Company’s Investigational New Drug application (IND)
application for a Phase 2 trial with NGC-Cap in metastatic or advanced breast cancer. Subsequently,
Processa initiated the Phase 2 study (NCT06568692) , which is a global, multicenter,
open-label, adaptive design trial comparing two different doses of NGC-Cap to FDA-approved
monotherapy capecitabine in approximately 60 to 90 patients. As agreed to with the FDA, the
breast cancer indication should lead to a more efficient development program while providing
a greater likelihood of approval. |
| ○ | The
NGC-Cap Phase 1b study evaluated ascending doses of capecitabine when combined with a fixed
dose of PCS6422 in patients with advanced, relapsed or refractory progressive gastrointestinal
cancer. These patients had to relapse from or fail all other treatments. NGC-Cap demonstrated
greater 5-FU exposure and lower fluoro-beta-alanine (FBAL) exposure with a better or similar
side-effect profile compared with monotherapy capecitabine, as well as preliminary anti-tumor
activity. In all evaluable patients who received one dose of PCS6422 and seven days of capecitabine,
partial responses or stable disease was observed in 66.7% (8 out of 12) of patients with
progression-free survival of approximately 5 to 11 months across these patients. |
| ○ | In
April 2024, Processa presented an abstract at the American Association for Cancer Research
(AACR) Annual Meeting 2024, including new Phase 1b data on NGC-Cap in patients with advanced,
relapsed or refractory progressive gastrointestinal cancer. NGC-Cap demonstrated 5-10 times
greater 5-FU exposure than monotherapy capecitabine at a significantly lower dose, along
with a favorable safety profile. As such, NGC-Cap holds potential for improved efficacy in
more patients due to a higher distribution of 5-FU to cancer cells.
Further, the extremely low exposure of FBAL, the primary catabolite formed from the
metabolism of 5-FU, across all NGC-Cap doses resulted in fewer catabolite-related side effects,
with only one patient having Grade 1 hand-foot-syndrome, an FBAL side effect that often requires
dose modifications. |
| ● | PCS3117:
Next-Generation Gemcitabine (NGC-Gem) |
| ○ | NGC-Gem
is an oral analog of gemcitabine (Gemzar®) that is converted to its active metabolite
by a different enzyme system, with potential for a positive response in gemcitabine patients
including those inherently resistant to or who acquire resistance to gemcitabine. |
| ○ | Processa
is evaluating the potential of NGC-Gem in patients with pancreatic and other cancers, as
well as ways to identify patients who are more likely to respond to NGC-Gem than gemcitabine
alone. The Company plans to meet with the FDA in late 2024 or early 2025 to discuss potential
trial designs, including implementation of the Project Optimus initiative. |
| ● | PCS11T:
Next-Generation Irinotecan (NGC-Iri) |
| ○ | NGC-Iri
is an analog of SN38, the active metabolite of irinotecan, that is expected to have an improved
safety-efficacy profile in every type of cancer where irinotecan is used. |
| ○ | As
announced earlier this month, two studies in a human melanoma xenograft mouse model measured
SN-38 in tumors, plasma and other tissues following administration of NGC-Iri, irinotecan
and Onivyde®, the liposomal formulation of irinotecan. One study compared
NGC-Iri with irinotecan, and the other compared irinotecan with Onivyde®.
The results found that mice administered NGC-Iri had greater accumulation of SN-38 in the
tumor compared with other tissues and that less SN-38 accumulated in non-cancer tissues,
which could lead to improved efficacy with a more favorable adverse event profile compared
with irinotecan and Onivyde®. |
| ○ | In
April 2024, Processa presented a second abstract at AACR titled “Application of phase
1 and pre-clinical data to assist in determining the optimal dosage regimen for cancer drugs
using the principles of Project Optimus.” This abstract describes the FDA Project Optimus
Initiative and draft optimal dosage regimen (ODR) guidance, which requires an ODR justified
by a dose-ranging efficacy and safety study, as opposed to a maximum tolerated dose approach.
Processa provided NGC-Iri preclinical study examples to demonstrate how the shape of the
exposure-response relationships for safety and efficacy can be determined from these pre-clinical
studies. By better understanding the exposure-response relationship earlier in the development
process, defining the recommended dose range and optimal dosage regimen becomes easier in
an efficacy-safety study, in a pivotal study, and for FDA approval. |
| ○ | The
Company is currently evaluating the manufacturing process and potential sites for NGC-Iri.
In addition, Processa is defining the potential paths to approval, which include defining
the target patient population and the type of cancer, with the expectation to conduct IND-enabling
toxicology studies in 2025. |
Second
Quarter Financial Results
Research
and development expenses for the second quarter of 2024 were $1.7 million, unchanged from the second quarter of 2023. General and administrative
expenses for the second quarter of 2024 were $1.4 million, compared with $1.0 million for the second quarter of 2023, primarily due to
an increase in professional fees.
The
net loss for the second quarter of 2024 was $3.0 million, or $1.01 per share, compared with the net loss for the second quarter of 2023
of $2.6 million, or $1.94 per share. All per-share figures reflect a 1-for-20 reverse stock split that was effective as of January 22,
2024.
Cash
and cash equivalents were $5.6 million as of June 30, 2024.
About
Processa Pharmaceuticals, Inc.
Processa
is a clinical-stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs with improved safety and
efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the
metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its
novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is
to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.
For
more information, visit our website at www.processapharma.com.
Forward-Looking
Statements
This
release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking
statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed
in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent
reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained
in the forward-looking statements.
Company
Contact:
Patrick
Lin
(925)
683-3218
plin@processapharma.com
Investor
Relations Contact:
Yvonne
Briggs
LHA
Investor Relations
(310)
691-7100
ybriggs@lhai.com
[Financial
Tables to follow]
PROCESSA
PHARMACEUTICALS, INC.
CONDENSED
CONSOLIDATED BALANCE SHEETS
(in
thousands, except share information)
(unaudited)
| |
June
30, 2024 | | |
December
31, 2023 | |
ASSETS | |
| | | |
| | |
Current Assets | |
| | | |
| | |
Cash and
cash equivalents | |
$ | 5,571 | | |
$ | 4,706 | |
Prepaid
expenses and other | |
| 1,907 | | |
| 926 | |
Total
Current Assets | |
| 7,478 | | |
| 5,632 | |
| |
| | | |
| | |
Property
and Equipment, net | |
| 2 | | |
| 3 | |
| |
| | | |
| | |
Other Assets | |
| | | |
| | |
Lease right-of-use assets,
net of accumulated amortization | |
| 115 | | |
| 146 | |
Security
deposit | |
| 6 | | |
| 6 | |
Total
Other Assets | |
| 121 | | |
| 152 | |
Total
Assets | |
$ | 7,601 | | |
$ | 5,787 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’
EQUITY | |
| | | |
| | |
Current Liabilities | |
| | | |
| | |
Current maturities of
lease liabilities | |
$ | 93 | | |
$ | 84 | |
Accounts payable | |
| 953 | | |
| 312 | |
Due to licensor | |
| - | | |
| 189 | |
Due to related parties | |
| - | | |
| - | |
Accrued
expenses | |
| 505 | | |
| 146 | |
Total
Current Liabilities | |
| 1,551 | | |
| 731 | |
Non-current Liabilities | |
| | | |
| | |
Non-current
lease liabilities | |
| 26 | | |
| 67 | |
Total
Liabilities | |
| 1,577 | | |
| 798 | |
| |
| | | |
| | |
Commitments and Contingencies | |
| - | | |
| - | |
| |
| | | |
| | |
Stockholders’ Equity | |
| | | |
| | |
Common stock, par value
$0.0001, 100,000,000 shares authorized: 2,873,883 issued and 2,868,883 outstanding at June 30, 2024; and 1,291,000 issued and 1,286,000
outstanding at December 31, 2023 | |
| 1 | | |
| - | |
Additional paid-in capital | |
| 87,429 | | |
| 80,658 | |
Treasury stock at cost — 5,000 shares
at June 30, 2024 and December 31, 2023 | |
| (300 | ) | |
| (300 | ) |
Accumulated
deficit | |
| (81,106 | ) | |
| (75,369 | ) |
Total
Stockholders’ Equity | |
| 6,024 | | |
| 4,989 | |
Total
Liabilities and Stockholders’ Equity | |
$ | 7,601 | | |
$ | 5,787 | |
PROCESSA
PHARMACEUTICALS, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(in
thousands, except per share data)
(unaudited)
| |
Three
Months Ended June 30, | | |
Six
Months Ended June 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Operating Expenses | |
| | | |
| | | |
| | | |
| | |
Research and
development expenses | |
$ | 1,730 | | |
$ | 1,688 | | |
$ | 3,270 | | |
$ | 3,343 | |
General
and administrative expenses | |
| 1,352 | | |
| 1,026 | | |
| 2,622 | | |
| 3,477 | |
| |
| | | |
| | | |
| | | |
| | |
Operating Loss | |
| (3,082 | ) | |
| (2,714 | ) | |
| (5,892 | ) | |
| (6,820 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other Income (Expense),
net | |
| 72 | | |
| 102 | | |
| 155 | | |
| 185 | |
| |
| | | |
| | | |
| | | |
| | |
Net Operating Loss Before Income Tax Benefit | |
| (3,010 | ) | |
| (2,612 | ) | |
| (5,737 | ) | |
| (6,635 | ) |
Income Tax Benefit | |
| - | | |
| - | | |
| - | | |
| - | |
| |
| | | |
| | | |
| | | |
| | |
Net Loss | |
$ | (3,010 | ) | |
$ | (2,612 | ) | |
$ | (5,737 | ) | |
$ | (6,635 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net Loss per Common
Share - Basic and Diluted | |
$ | (1.01 | ) | |
$ | (1.94 | ) | |
$ | (2.11 | ) | |
$ | (5.34 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted Average Common
Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted | |
| 2,983,283 | | |
| 1,346,808 | | |
| 2,724,903 | | |
| 1,243,475 | |
#
# #
v3.24.2.u1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Processa Pharmaceuticals (NASDAQ:PCSA)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Processa Pharmaceuticals (NASDAQ:PCSA)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024